• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

DRL announces the launch of Cefixime in the US

expressbpdAugust 29, 2017

Tag: DRL , Cefixime , FDA

DRL announces the launch of Cefixime in the US - BPD

Dr Reddy’s Laboratories (DRL) has launched Cefixime for Oral Suspension, USP 100 mg/5mL and 200 mg/5mL, a therapeutic equivalent generic version of Suprax for Oral Suspension, approved by the US Food and Drug Administration (USFDA).

DRL’s Cefixime for Oral Suspension, USP is available in strengths of 100 mg/5mL and 200 mg/5mL after reconstitution. The 100 mg/5 mL strength is available in 50 mL bottles. The 200 mg/5 mL strength is available in 75 mL and 50 mL bottles.

Previous:Jubilant Life gets US FDA nod for anti-inflammatory drug

Next:Danone India launches Neocate in India

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

DRL announces the launch of Cefixime in the US | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

Cilostazol(FDA Approved) (Micronized)

Cilostazol(FDA Approved) (Micronized)
Cefixime capsules

Cefixime capsules
Deoxycyline (FDA)

Deoxycyline (FDA)
Tobramycin base( FDA)

Tobramycin base( FDA)
Cefixime for oral suspension 100mg/5ml

Cefixime for oral suspension 100mg/5ml
Ivermectin (FDA)

Ivermectin (FDA)
Cefixime

Cefixime
cefixime

cefixime
Cefixime

Cefixime
Fosphenytoin sodium (FDA)

Fosphenytoin sodium (FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service